MedPath

A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Phase 3
Recruiting
Conditions
Colon Cancer
Interventions
Drug: CAPEOX
Registration Number
NCT06686576
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Brief Summary

The goal of this clinical trial is to evaluate the efficacy of perioperative QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
288
Inclusion Criteria
  • Signed written informed consent;
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Untreated pathologically confirmed colon adenocarcinoma
  • Radiographic assessment showed a resectable stage IIB-III based on AJCC Stage VIII (cT4 or cN+ only).
  • Has a tumor demonstrating the presence of MSI-H/ dMMR
  • Adequate organ function as described in the protocol
Exclusion Criteria
  • Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc
  • Has distant metastatic disease.
  • Has an active autoimmune disease that has required systemic treatment in past 2 years
  • Has know history of, or any evidence of interstitial lung disease;
  • Has an active infection requiring systemic therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupQL1706Phase Ib/Ⅲ Participants will receive QL1706 pre and post surgery
Phase III Control groupCAPEOXParticipants will receive SOC (CAPEOX) or undergo expectant observation post surgery.
Primary Outcome Measures
NameTimeMethod
Pathological Complete Response(pCR), defined as the proportion of subjects with no residual tumor in the primary tumor removed and in all lymph nodes removed after neoadjuvant therapy.1 month after surgery
Event Free Survival, EFS(EFS), defined as the time from randomization to either disease recurrence or death due to any cause or treatment related toxicity that results in the participant not being suitable for surgery.Up to approximately 5 years
Secondary Outcome Measures
NameTimeMethod
R0 tumor resection rate2 week after surgery

R0 tumor resection rate is defined as the proportion of subjects with R0 excision

Overall Survival (OS)Up to approximately 5 years

OS is defined as time from randomization to death from any cause

Number of Participants with treatment emergent adverse events (AEs), serious adverse events (SAEs), Immune-mediated Adverse Event (imAEs), AEs leading to death and AEs leading to discontinuation of study treatmentUp to approximately 5 years

Trial Locations

Locations (1)

Affiliated Cancer Hospital of Sun Yat-sen University

🇨🇳

Guangzhou, China

Affiliated Cancer Hospital of Sun Yat-sen University
🇨🇳Guangzhou, China
Rui hua Xu, PhD
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.